Involving 188 patients, the study revealed no significant increase in grade ≥ 3 hematologic toxicities, such as anemia or neutropenia, among patients receiving both treatments compared to those treated with CDK4/6 inhibitors alone. Here, CDK4 is linked to anemia (phenotype).